TY - JOUR
T1 - Medical castration produced by the GnRH analogue leuprolide to treat metastatic breast cancer
AU - Harvey, Harold
AU - Lipton, Allan
AU - Max, D. T.
AU - Pearlman, H. G.
AU - Diaz-Perches, R.
AU - de la Garza, J.
PY - 1985
Y1 - 1985
N2 - Leuprolide (Lupron, TAP Pharmaceuticals, North Chicago), a gonadotropin-releasing hormone analogue, was administered to 26 premenopausal women with metastatic breast cancer. Of 25 evaluable patients, 11 (44%) had a partial response with a medium duration of 39 weeks and five (20%) remained stable. Six patients showed early rapid progression of their disease. Toxicity was mild and included hot flashes, nausea, vomiting, and headache. Leuprolide induced amenorrhea in all patients who received treatment for ten weeks or longer. We conclude that this GnRH analogue provides a safe and effective means of producing medical castration in premenopausal patients with metastatic breast carcinoma.
AB - Leuprolide (Lupron, TAP Pharmaceuticals, North Chicago), a gonadotropin-releasing hormone analogue, was administered to 26 premenopausal women with metastatic breast cancer. Of 25 evaluable patients, 11 (44%) had a partial response with a medium duration of 39 weeks and five (20%) remained stable. Six patients showed early rapid progression of their disease. Toxicity was mild and included hot flashes, nausea, vomiting, and headache. Leuprolide induced amenorrhea in all patients who received treatment for ten weeks or longer. We conclude that this GnRH analogue provides a safe and effective means of producing medical castration in premenopausal patients with metastatic breast carcinoma.
UR - https://www.scopus.com/pages/publications/0021819774
UR - https://www.scopus.com/pages/publications/0021819774#tab=citedBy
U2 - 10.1200/JCO.1985.3.8.1068
DO - 10.1200/JCO.1985.3.8.1068
M3 - Article
C2 - 3926958
AN - SCOPUS:0021819774
SN - 0732-183X
VL - 3
SP - 1068
EP - 1072
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 8
ER -
